The Selectivity Advantage The pivotal 1998 study by Raun and colleagues at Novo Nordisk characterized ipamorelin as "the first selective growth hormone secretagogue." The key finding was that even at doses far exceeding those required for GH release, ipamorelin did not produce meaningful elevations in ACTH, cortisol, prolactin, aldosterone, or thyroid-stimulating hormone
Its mechanism suggests potential benefit, but without validated dosing protocols or safety data in ischemic models, using it as a primary intervention introduces unquantified risk and reduces study reproducibility
Before you add the water, double-check your desired concentration and your calculation
Comparing Effectiveness: Which Method is Best
Here we developed a high-throughput screen to identify compounds that modulate the metabolic activity of intracellular Staphylococcus aureus
Transgenic expression of cholesterol-7--hydroxylase prevents atherosclerosis in C57BL/6J mice